The endocannabinoid system is also invlolved in many gastrointestinal physiological and physiopathological actions (Marquez, L. *et al.*, *PLoS One* **2009**, *4*, e6893). All these effects are driven mainly via cannabinoid receptors (CBRs), CB1 and CB2. CB1 receptors are present throughout the GI tract of animals and healthy humans, especially in the enteric nervous system (ENS) and the epithelial lining, as well as smooth muscle cells of blood vessels in the colonic wall (Wright, K. *et al.*, *Gastroenterology* **2005**, *129*, 437; Duncan, M. *et al.*, *Aliment. Pharmacol. Ther.* **2005**, *22*, 667). Activation of CB1 produces anti-emetic, anti-motility, and anti-inflammatory effect, and help to modulate pain (Perisetti, A. *et al.*, *Ann. Gastroenterol.* **2020**, *33*, 134). CB2 receptors are expressed in immune cells such as plasma cells and macrophages, in the lamina propria of the GI tract (Wright, K. *et al.*, *Gastroenterology* **2005**, *129*, 437), and primarily on the epithelium of human colonic tissue associated with inflammatory bowel disease (IBD). Activation of CB2 exerts anti-inflammatory effect by reducing pro-inflammatory cytokines. Expression of MAGL is increased in colonic tissue in UC patients (Marquez, L. *et al.*, *PLoS One* **2009**, *4*, e6893) and 2-AG levels are increased in plasma of IBD patients (Grill, M. *et al.*, *Sci. Rep.* **2019**, *9*, 2358). Several animal studies have demonstrated the potential of MAGL inhibitors for symptomatic treatment of IBD. MAGL inhibition prevents TNBS-induced mouse colitis and decreases local and circulating inflammatory markers via a CB1/CB2 MoA (Marquez, L. *et al.*, *PLoS One* **2009**, *4*, e6893). Furthermore, MAGL inhibition improves gut wall integrity and intestinal permeability via a CB1 driven MoA (Wang, J. *et al.*, *Biochem. Biophys. Res. Commun.* **2020**, *525*, 962).

In conclusion, suppressing the action and/or the activation of MAGL is a promising new therapeutic strategy for the treatment or prevention of neuroinflammation, neurodegenerative diseases, pain, cancer, mental disorders, inflammatory bowel disease, abdominal pain and abdominal pain associated with irritable bowel syndrome. Furthermore, suppressing the action and/or the activation of MAGL is a promising new therapeutic strategy for providing neuroprotection and myelin regeneration. Accordingly, there is a high unmet medical need for new MAGL inhibitors.

Summary ~~of the Invention~~

~~In a first aspect, the~~The present ~~invention~~disclosure provides a compound of formula (I), or a pharmaceutically acceptable salt thereof,



(I)

wherein B, C, L, X, Y, R_L and R^3 to R^5 are as described herein.

In one aspect, the present disclosure provides a compound of formula (I)



(I)

or a pharmaceutically acceptable salt thereof, wherein:

X is selected from O, NH, N(C_{1-6}-alkyl) and $(CH_2)_mCHR^6$; and Y is $(CH_2)_nCHR^7$; or X and Y together form a group $–CR^6=CR^7–$;

m and n are each independently an integer selected from 0 and 1;

L is selected from a covalent bond, SO_2, $–SO_2NH–$, $–NHSO_2–$, $–SO_2NH$-C_{1-6}-alkyl–, $–C_{1-6}$-alkyl-$NHSO_2–$, $–CHR^8–$, –O–, –NH–, $–OCH_2–$, $–CH_2O–$, $–CH_2NH–$, $–NHCH_2–$, $–CH_2N(C_{1-6}$-alkyl)–, $–N(C_{1-6}$-alkyl)$CH_2–$, $–CH_2OCH_2–$, $–CF_2CH_2–$, $–CH_2CF_2–$, $–CH_2CH_2–$, –CH=CH– and –C≡C–;

L^D is selected from a covalent bond, SO_2, –O–, $–NR^{11}–$, $–CH_2NH–$;

A is selected from



; ; ; ; ; ; ; and ;

B is selected from



; ;



;



;



;



;



;



; and



;

C is selected from


;

;

;

;

;

;

;

and


;

D is selected from C_6-C_{14}-aryl, C_3-C_{10}-cycloalkyl, 5-14-membered heteroaryl, and 3- to 14-membered heterocyclyl;

R_L is selected from C_{1-6}-alkyl and a group 

;

R^1 and R^2 are independently selected from hydrogen, halogen, SF_5, cyano, carbamoyl, sulfamoyl, C_{1-6}-alkyl, C_{1-6}-alkoxy, halo-C_{1-6}-alkyl, halo-C_{1-6}-alkoxy, C_{1-6}-alkyl-SO_2–, halo-C_{1-6}-alkyl-SO_2–, cyano-C_{1-6}-alkyl-SO_2–, and a group



;

R^3 is selected from hydrogen, halogen, hydroxy, cyano, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, C_{1-6}-alkoxy and halo-C_{1-6}-alkoxy;

R^4 and R^5 are independently selected from hydrogen, halogen, cyano, hydroxy, amino, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, C_{1-6}-alkoxy, halo-C_{1-6}-alkoxy and oxo;

R^6 and R^7 are independently selected from hydrogen, halogen, hydroxy and C_{1-6}-alkyl; or

R^6 and R^7, taken together with the carbon atoms to which they are attached, form a C_3-C_{10}-cycloalkyl ring;

R^8 is selected from hydrogen, C_6-C_{14}-aryl and halo-C_6-C_{14}-aryl;

R^9 is selected from hydrogen, hydroxy, oxo, halogen, cyano, carbamoyl, C_{1-6}-alkyl, C_3-C_{10}-cycloalkyl, C_{1-6}-alkoxy, halo-C_{1-6}-alkyl, hydroxy-C_{1-6}-alkyl, halo-C_{1-6}-alkoxy, cyano-C_{1-6}-alkyl, cyano-C_{1-6}-alkoxy, C_{1-6}-alkyl-SO_2-C_{1-6}-alkyl–, C_{1-6}-alkyl-SO_2–, C_{1-6}-alkoxy-carbonyl, halo-C_{1-6}-alkyl-SO_2–, cyano-C_{1-6}-alkyl-SO_2–, C_{1-6}-alkyl-SO– and C_{1-6}-alkyl-S–, wherein said C_3-C_{10}-cycloalkyl is optionally substituted with one halo-C_1-C_6-alkyl;

R^{10} is selected from hydrogen, halogen, hydroxy, oxo, C_{1-6}-alkyl, and halo-C_{1-6}-alkyl; and

R^{11} is selected from hydrogen, C_{1-6}-alkyl, C_{1-6}-alkoxy-C_{1-6}-alkyl, and C_{3-10}-cycloalkyl-C_{1-6}-alkyl–, C_6-C_{14}-aryl.

~~In one aspect, the~~The present ~~invention~~disclosure provides processes of manufacturing the compounds of formula (I), or pharmaceutically acceptable salts thereof, described herein.

~~In a further aspect, the~~The present ~~invention~~disclosure provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, when manufactured according to the processes described herein.

In a further aspect, the present ~~invention~~disclosure provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, for use as therapeutically active substance.

In a further aspect, the present ~~invention~~disclosure provides a pharmaceutical composition comprising a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, and a therapeutically inert carrier.

~~In a further aspect, the~~The present ~~invention~~disclosure provides the use of a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, or of a pharmaceutical composition described herein for inhibiting monoacylglycerol lipase (MAGL) in a mammal.

~~In a further aspect, the~~The present ~~invention~~disclosure provides the use of a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, or of a pharmaceutical composition described herein for the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer, mental disorders and/or inflammatory bowel disease in a mammal.

In a further aspect, the present disclosure provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as described herein for use in the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer, mental disorders and/or inflammatory bowel disease in a mammal.

In a further aspect, the present disclosure provides use of a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer, mental disorders and/or inflammatory bowel disease in a mammal.

~~In a further aspect, the~~The present ~~invention~~disclosure provides the use of a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, or of a pharmaceutical composition described herein for the treatment or prophylaxis of multiple

sclerosis, Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain,

spasticity associated with pain, abdominal pain, abdominal pain associated with irritable bowel syndrome and/or visceral pain in a mammal.

In a further aspect, the present disclosure provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as described herein for use in the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain, spasticity associated with pain, abdominal pain, abdominal pain associated with irritable bowel syndrome and/or visceral pain in a mammal.

In a further aspect, the present disclosure provides use of a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain, spasticity associated with pain, abdominal pain, abdominal pain associated with irritable bowel syndrome and/or visceral pain in a mammal.

Detailed Description of the Invention

Definitions

Features, integers, characteristics, compounds, chemical moieties or groups described in conjunction with a particular aspect, embodiment or example of the invention are to be understood to be applicable to any other aspect, embodiment or example described herein, unless incompatible therewith. All of the features disclosed in this specification (including any accompanying claims, abstract and drawings), and/or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations where at least some of such features and/or steps are mutually exclusive. The invention is not restricted to the details of any foregoing embodiments. The invention extends to any novel one, or any novel combination,

of the features disclosed in this specification (including any accompanying claims, abstract and drawings), or to any novel one, or any novel combination, of the steps of any method or process so disclosed.

The term “alkyl” refers to a mono- or multivalent, e.g., a mono- or bivalent, linear or branched saturated hydrocarbon group of 1 to 12 carbon atoms. In some preferred embodiments, the alkyl group contains 1 to 6 carbon atoms (“C_{1-6}-alkyl”), e.g., 1, 2, 3, 4, 5, or 6 carbon atoms. In other embodiments, the alkyl group contains 1 to 3 carbon atoms, e.g., 1, 2 or 3 carbon atoms. Some non-limiting examples of alkyl include methyl, ethyl, propyl, 2-propyl (isopropyl), n-butyl, iso-butyl, sec-butyl, tert-butyl, and 2,2-dimethylpropyl. A particularly preferred, yet non-limiting example of alkyl is methyl.

The term “alkoxy” refers to an alkyl group, as previously defined, attached to the parent molecular moiety via an oxygen atom. Unless otherwise specified, the alkoxy group contains 1 to 12 carbon atoms. In some preferred embodiments, the alkoxy group contains 1 to 6 carbon atoms (“C_{1-6}-alkoxy”). In other embodiments, the alkoxy group contains 1 to 4 carbon atoms. In still other embodiments, the alkoxy group contains 1 to 3 carbon atoms. Some non-limiting examples of alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy and tert-butoxy. A particularly preferred, yet non-limiting example of alkoxy is methoxy.

CLAIMS

1. A compound of formula (I)



(I)

or a pharmaceutically acceptable salt thereof, wherein:

X is selected from O, NH, N(C_{1-6}-alkyl) and $(CH_2)_mCHR^6$; and Y is $(CH_2)_nCHR^7$; or

X and Y together form a group $–CR^6=CR^7–$;

m and n are each independently an integer selected from 0 and 1;

L is selected from a covalent bond, SO_2, $–SO_2NH–$, $–NHSO_2–$, $–SO_2NH$-C_{1-6}-alkyl–, $–C_{1-6}$-alkyl-$NHSO_2–$, $–CHR^8–$, –O–, –NH–, $–OCH_2–$, $–CH_2O–$, $–CH_2NH–$, $–NHCH_2–$, $–CH_2N(C_{1-6}$-alkyl)–, $–N(C_{1-6}$-alkyl)$CH_2–$, $–CH_2OCH_2–$, $–CF_2CH_2–$, $–CH_2CF_2–$, $–CH_2CH_2–$, –CH=CH– and –C≡C–;

L^D is selected from a covalent bond, SO_2, –O–, $–NR^{11}–$, $–CH_2NH–$;

A is selected from

 ;  ;  ;  ;  ;  ;  ; and  ;

B is selected from



;


;



;


;



;


;



;


; and


;

C is selected from


;

;

;

;

;

;

;

;


and ;

D is selected from C_6-C_{14}-aryl, C_3-C_{10}-cycloalkyl, 5-14-membered heteroaryl, and 3- to 14-membered heterocyclyl;

R_L is selected from C_{1-6}-alkyl and a group 

;

R^1 and R^2 are independently selected from hydrogen, halogen, SF_5, cyano, carbamoyl, sulfamoyl, C_{1-6}-alkyl, C_{1-6}-alkoxy, halo-C_{1-6}-alkyl, halo-C_{1-6}-alkoxy, C_{1-6}-alkyl-SO_2–, halo-C_{1-6}-alkyl-SO_2–, cyano-C_{1-6}-alkyl-SO_2–, and a group 

;

R^3 is selected from hydrogen, halogen, hydroxy, cyano, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, C_{1-6}-alkoxy and halo-C_{1-6}-alkoxy;

R^4 and R^5 are independently selected from hydrogen, halogen, cyano, hydroxy, amino, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, C_{1-6}-alkoxy, halo-C_{1-6}-alkoxy and oxo;

R^6 and R^7 are independently selected from hydrogen, halogen, hydroxy and C_{1-6}-alkyl; or

R^6 and R^7, taken together with the carbon atoms to which they are attached, form a C_3-C_{10}-cycloalkyl ring;

R^8 is selected from hydrogen, C_6-C_{14}-aryl and halo-C_6-C_{14}-aryl;

R^9 is selected from hydrogen, hydroxy, oxo, halogen, cyano, carbamoyl, C_{1-6}-alkyl, C_3-C_{10}-cycloalkyl, C_{1-6}-alkoxy, halo-C_{1-6}-alkyl, hydroxy-C_{1-6}-alkyl, halo-C_{1-6}-alkoxy, cyano-C_{1-6}-alkyl, cyano-C_{1-6}-alkoxy, C_{1-6}-alkyl-SO_2-C_{1-6}-alkyl–, C_{1-6}-alkyl-SO_2–, C_{1-6}-alkoxy-carbonyl, halo-C_{1-6}-alkyl-SO_2–, cyano-C_{1-6}-alkyl-SO_2–, C_{1-6}-alkyl-SO– and C_{1-6}-alkyl-S–, wherein said C_3-C_{10}-cycloalkyl is optionally substituted with one halo-C_1-C_6-alkyl;

R^{10} is selected from hydrogen, halogen, hydroxy, oxo, C_{1-6}-alkyl, and halo-C_{1-6}-alkyl; and

R^{11} is selected from hydrogen, C_{1-6}-alkyl, C_{1-6}-alkoxy-C_{1-6}-alkyl, and C_{3-10}-cycloalkyl-C_{1-6}-alkyl–, C_6-C_{14}-aryl.

2. The compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:

X is selected from O, NH, N(C_{1-6}-alkyl) and $(CH_2)_mCHR^6$;

Y is $(CH_2)_nCHR^7$;

m and n are each independently an integer selected from 0 and 1;

R^6 is selected from hydrogen, halogen, hydroxy and C_{1-6}-alkyl; and

R^7 is hydrogen.

3. The compound of formula (I) according to claim 2, or a pharmaceutically acceptable salt thereof, wherein:

X is selected from N(C_{1-6}-alkyl) and $(CH_2)_mCHR^6$;

Y is $(CH_2)_nCHR^7$;

m is 0;

n is an integer selected from 0 and 1; and

R^6 and R^7 are both hydrogen.

4. The compound of formula (I) according to claim 3, or a pharmaceutically acceptable salt thereof, wherein:

X is selected from N-methyl and $(CH_2)_mCHR^6$;

Y is $(CH_2)_nCHR^7$;

m is 0;

n is an integer selected from 0 and 1; and

R^6 and R^7 are both hydrogen.

5. The compound of formula (I) according to any one of claims 1to 4, or a pharmaceutically acceptable salt thereof, wherein:

L is selected from a covalent bond, $–CHR^8–$, $–CH_2O–$, SO_2, $–SO_2NH–$, $–SO_2NH\text{-}C_{1\text{-}6}\text{-alkyl}–$, –O–, –NH–, $–CH_2NH–$, $–CH_2N(C_{1\text{-}6}\text{-alkyl})–$, and –C≡C–;

L^D is selected from a covalent bond, SO_2, –O–, $–NR^{11}–$, and $–CH_2NH–$;

R^1 is selected from halogen, SF_5, sulfamoyl, $C_{1\text{-}6}$-alkyl, halo-$C_{1\text{-}6}$-alkyl, $C_{1\text{-}6}$-alkyl-$SO_2–$, halo-$C_{1\text{-}6}$-alkyl-$SO_2–$, cyano-$C_{1\text{-}6}$-alkyl-$SO_2–$, C_3-C_{10}-cycloalkyl-$SO_2–$, C_6-C_{14}-aryl-$SO_2–$, halo-$C_{1\text{-}6}$-alkoxy, and a group



;

R^2 is selected from hydrogen, $C_{1\text{-}6}$-alkyl-$SO_2–$ and halogen;

R^8 is selected from hydrogen and C_6-C_{14}-aryl;

R^9 is selected from hydrogen, hydroxy, oxo, halogen, cyano, carbamoyl, $C_{1\text{-}6}$-alkyl, C_3-C_{10}-cycloalkyl, $C_{1\text{-}6}$-alkoxy, halo-$C_{1\text{-}6}$-alkyl, hydroxy-$C_{1\text{-}6}$-alkyl, halo-$C_{1\text{-}6}$-alkoxy, $C_{1\text{-}6}$-alkyl-SO_2-$C_{1\text{-}6}$-alkyl–, $C_{1\text{-}6}$-alkyl-$SO_2–$, $C_{1\text{-}6}$-alkoxy-carbonyl, wherein said C_3-C_{10}-cycloalkyl is optionally substituted with one halo-C_1-C_6-alkyl;

R^{10} is selected from hydrogen, halogen, hydroxy, oxo, $C_{1\text{-}6}$-alkyl, and halo-$C_{1\text{-}6}$-alkyl; and

R^{11} is selected from hydrogen, $C_{1\text{-}6}$-alkyl, $C_{1\text{-}6}$-alkoxy-$C_{1\text{-}6}$-alkyl, and $C_{3\text{-}10}$-cycloalkyl-$C_{1\text{-}6}$-alkyl–, C_6-C_{14}-aryl.

6. The compound of formula (I) according to claim 5, or a pharmaceutically acceptable salt thereof, wherein:

L is selected from a covalent bond, $–CHR^8–$, $–CH_2O–$, SO_2, $–SO_2NH–$, $–SO_2NH\text{-}C_{1\text{-}6}\text{-alkyl}–$, –O–, –NH–, $–CH_2NH–$, $–CH_2N(C_{1\text{-}6}\text{-alkyl})–$, and –C≡C–;

L^D is selected from a covalent bond, SO_2, –O–, $–NR^{11}–$, and $–CH_2NH–$;

D is selected from:



and ;

R^1 is selected from halogen, SF_5, sulfamoyl, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, C_{1-6}-alkyl-SO_2–, halo-C_{1-6}-alkyl-SO_2–, cyano-C_{1-6}-alkyl-SO_2–, C_3-C_{10}-cycloalkyl-SO_2–, C_6-C_{14}-aryl-SO_2–, halo-C_{1-6}-alkoxy, and a group



;

R^2 is selected from hydrogen, C_{1-6}-alkyl-SO_2– and halogen;

R^8 is selected from hydrogen and C_6-C_{14}-aryl;

R^9 is selected from hydrogen, hydroxy, oxo, halogen, cyano, carbamoyl, C_{1-6}-alkyl, C_3-C_{10}-cycloalkyl, C_{1-6}-alkoxy, halo-C_{1-6}-alkyl, hydroxy-C_{1-6}-alkyl, halo-C_{1-6}-alkoxy, C_{1-6}-alkyl-SO_2-C_{1-6}-alkyl–, C_{1-6}-alkyl-SO_2–, C_{1-6}-alkoxy-carbonyl, wherein said C_3-C_{10}-cycloalkyl is optionally substituted with one halo-C_1-C_6-alkyl;

R^{10} is selected from hydrogen, halogen, hydroxy, oxo, C_{1-6}-alkyl, and halo-C_{1-6}-alkyl; and

R^{11} is selected from hydrogen, C_{1-6}-alkyl, C_{1-6}-alkoxy-C_{1-6}-alkyl, and C_{3-10}-cycloalkyl-C_{1-6}-alkyl–, C_6-C_{14}-aryl.

7. The compound of formula (I) according to claim 6, or a pharmaceutically acceptable salt thereof, wherein:

R_L is a group 

;

L is selected from a covalent bond, $–CHR^8–$, and $–CH_2O–$;

L^D is selected from a covalent bond, –O–, and $–NR^{11}–$;

A is selected from

 ;  ;  ; and  ;

D is selected from:

 ;  ;  ;  ;  ;  ; and 
;

R^1 is selected from halo-C_{1-6}-alkyl and a group



;

R^2 is selected from hydrogen and halogen;

R^8 is hydrogen;

R^9 is selected from hydrogen, halogen, halo-C_{1-6}-alkyl, halo-C_{1-6}-alkoxy, and C_{1-6}-alkyl-SO_2–;

R^{10} is selected from hydrogen, halogen, and halo-C_{1-6}-alkyl; and

R^{11} is selected from C_{1-6}-alkyl and C_{3-10}-cycloalkyl-C_{1-6}-alkyl–.

8. The compound of formula (I) according to claim 7, or a pharmaceutically acceptable salt thereof, wherein:

R_L is a group 

;

L is selected from a covalent bond, $–CHR^8–$, and $–CH_2O–$;

L^D is selected from a covalent bond, –O–, and $–NR^{11}–$;

A is selected from

 ;  ;  ; and  ;

D is selected from:

 ;  ;  ;  ;  ;  ; and 

;

R^1 is selected from CF_3 and a group  ;

R^2 is selected from hydrogen and fluoro;

R^8 is hydrogen;

R^9 is selected from hydrogen, fluoro, chloro, CF_3, 2,2,2-trifluoroethoxy, and methylsulfonyl;

R^{10} is selected from hydrogen, chloro, and CF_3; and

R^{11} is selected from methyl and cyclopropylmethyl.

9. The compound of formula (I) according to any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, wherein:

B is selected from

 ;  ;

 ; and

 ; and

R^3 is hydrogen.

10. The compound of formula (I) according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein:

C is selected from

 ;  ;  ;  ;  ;  ;  and

 ;

R^4 is selected from hydrogen and oxo; and

R^5 is selected from hydrogen and C_{1-6}-alkyl.

11. The compound of formula (I) according to claim 10, or a pharmaceutically acceptable salt thereof, wherein:

C is selected from

 and  ;

R^4 is oxo; and

R^5 is hydrogen.

12. The compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:

X is selected from O, NH, N(C_{1-6}-alkyl) and $(CH_2)_mCHR^6$;

Y is $(CH_2)_nCHR^7$;

m and n are each independently an integer selected from 0 and 1;

L is selected from a covalent bond, $–CHR^8–$, $–CH_2O–$, SO_2, $–SO_2NH–$, $–SO_2NH$-C_{1-6}-alkyl–, –O–, –NH–, $–CH_2NH–$, $–CH_2N(C_{1-6}$-alkyl)–, and –C≡C–;

L^D is selected from a covalent bond, SO_2, –O–, $–NR^{11}–$, and $–CH_2NH–$;

A is selected from

 ;  ;  ;  ;  ; ;  ; and  ;

B is selected from



; 

;



; 

;



; 

;



; 

; and



;

C is selected from


; 
; 
; 
; 
; 
; 
and


;

D is selected from:


; 
; 
; 
; 
; 
; 
; 
;


; 
; 
; 
; 
; 
;

 ;  ;  ;  ;  ;  ;  ;  ;

and  ;

R^1 is selected from halogen, SF_5, sulfamoyl, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, C_{1-6}-alkyl-SO_2–, halo-C_{1-6}-alkyl-SO_2–, cyano-C_{1-6}-alkyl-SO_2–, C_3-C_{10}-cycloalkyl-SO_2–, C_6-C_{14}-aryl-SO_2–, halo-C_{1-6}-alkoxy, and a group



;

R^2 is selected from hydrogen, C_{1-6}-alkyl-SO_2– and halogen;

R^3 and R^7 are both hydrogen;

R^4 is selected from hydrogen and oxo;

R^5 is selected from hydrogen and C_{1-6}-alkyl;

R^6 is selected from hydrogen, halogen, hydroxy and C_{1-6}-alkyl;

R^8 is selected from hydrogen and C_6-C_{14}-aryl;

R^9 is selected from hydrogen, hydroxy, oxo, halogen, cyano, carbamoyl, C_{1-6}-alkyl, C_3-C_{10}-cycloalkyl, C_{1-6}-alkoxy, halo-C_{1-6}-alkyl, hydroxy-C_{1-6}-alkyl, halo-C_{1-6}-alkoxy, C_{1-6}-alkyl-SO_2-C_{1-6}-alkyl–, C_{1-6}-alkyl-SO_2–, C_{1-6}-alkoxy-carbonyl, wherein said C_3-C_{10}-cycloalkyl is optionally substituted with one halo-C_1-C_6-alkyl;

R^{10} is selected from hydrogen, halogen, hydroxy, oxo, C_{1-6}-alkyl, and halo-C_{1-6}-alkyl; and

R^{11} is selected from hydrogen, C_{1-6}-alkyl, C_{1-6}-alkoxy-C_{1-6}-alkyl, and C_{3-10}-cycloalkyl-C_{1-6}-alkyl–, C_6-C_{14}-aryl.

13. The compound of formula (I) according to claim 12, or a pharmaceutically acceptable salt thereof, wherein:

X is selected from N(C_{1-6}-alkyl) and $(CH_2)_mCHR^6$;

Y is $(CH_2)_nCHR^7$;

m is 0;

n is an integer selected from 0 and 1;

L is selected from a covalent bond, $–CHR^8–$, and $–CH_2O–$;

L^D is selected from a covalent bond, –O–, and $–NR^{11}–$;

A is selected from


;

;

; and

;

B is selected from



;


;



; and



;

C is selected from


and

;

D is selected from:


; and

;

R_L is a group


;

R^1 is selected from halo-C_{1-6}-alkyl and a group



;

R^2 is selected from hydrogen and halogen;

R^3, R^5, R^6, R^7 and R^8 are all hydrogen;

R^4 is selected from hydrogen and oxo;

R^9 is selected from hydrogen, halogen, halo-C_{1-6}-alkyl, halo-C_{1-6}-alkoxy, and C_{1-6}-alkyl-SO_2–;

R^{10} is selected from hydrogen, halogen, and halo-C_{1-6}-alkyl; and

R^{11} is selected from C_{1-6}-alkyl and C_{3-10}-cycloalkyl-C_{1-6}-alkyl–.

14. The compound of formula (I) according to claim 13, or a pharmaceutically acceptable salt thereof, wherein:

X is selected from N(methyl) and $(CH_2)_mCHR^6$;

Y is $(CH_2)_nCHR^7$;

m is 0;

n is an integer selected from 0 and 1;

L is selected from a covalent bond, –CHR^8–, and –CH_2O–;

L^D is selected from a covalent bond, –O–, and –NR^{11}–;

A is selected from phenyl, pyridyl, pyrazinyl, and pyrimidinyl;

B is selected from



;



;



; and



;

C is selected from



;

D is selected from phenyl, cyclopropyl, spiro[3.3]heptan-2-yl, cyclobutyl, cyclohexyl, 2-azaspiro[3.4]octan-2-yl, azetidinyl, and pyrrolidinyl;

R_L is a group 

;

R^1 is selected from CF_3 and a group 

;

R^2 is selected from hydrogen and fluoro;

R^3, R^5, R^6, R^7 and R^8 are all hydrogen;

R^4 is selected from hydrogen and oxo;

R^9 is selected from hydrogen, fluoro, chloro, CF_3, 2,2,2-trifluoroethoxy, and methylsulfonyl;

R^{10} is selected from hydrogen, chloro, and CF_3; and

R^{11} is selected from methyl and cyclopropylmethyl.

15. The compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, selected from:

(-)-5-[3-[3-[[2-fluoro-4-(trifluoromethyl)phenyl]methoxy]azetidin-1-yl]-3-oxo-propyl]pyrrolidin-2-one;

(+)-5-[3-[3-[[2-fluoro-4-(trifluoromethyl)phenyl]methoxy]azetidin-1-yl]-3-oxo-propyl]pyrrolidin-2-one;

(-)-[3-[3-(4-tert-Butylphenyl)azetidin-1-yl]-3-oxo-propyl]pyrrolidin-2-one;

(+)-5-[3-[3-(4-tert-Butylphenyl)azetidin-1-yl]-3-oxo-propyl]pyrrolidin-2-one;

(-)-5-[3-Oxo-3-[3-[4-[1-(trifluoromethyl)cyclopropyl]phenyl]azetidin-1-yl]propyl]pyrrolidin-2-one;

(+)-5-[3-Oxo-3-[3-[4-[1-(trifluoromethyl)cyclopropyl]phenyl]azetidin-1-yl]propyl]pyrrolidin-2-one;

(-)- or (+)-5-[3-Oxo-3-[3-[4-(2,2,2-trifluoroethyl)phenyl]azetidin-1-yl]propyl]pyrrolidin-2-one;

(+)- or (-)-5-[3-Oxo-3-[3-[4-(2,2,2-trifluoroethyl)phenyl]azetidin-1-yl]propyl]pyrrolidin-2-one;

(-)-5-[3-[3-[4-(2,4-Difluorophenyl)phenyl]azetidin-1-yl]-3-oxo-propyl]pyrrolidin-2-one;

(+)-5-[3-[3-[4-(2,4-Difluorophenyl)phenyl]azetidin-1-yl]-3-oxo-propyl]pyrrolidin-2-one;

(-)-5-[3-Oxo-3-[rac-(3aS,6aS)-2-[[2-fluoro-4-(trifluoromethyl)phenyl]methyl]-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]propyl]pyrrolidin-2-one;

(+)-5-[3-Oxo-3-[rac-(3aS,6aS)-2-[[2-fluoro-4-(trifluoromethyl)phenyl]methyl]-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]propyl]pyrrolidin-2-one;

(-)- or (+)-5-[3-[3-[[2-Fluoro-4-(trifluoromethyl)phenyl]methoxy]azetidin-1-yl]-3-oxo-propyl]-5-methyl-pyrrolidin-2-one;

(+)- or (-)-5-[3-[3-[[2-Fluoro-4-(trifluoromethyl)phenyl]methoxy]azetidin-1-yl]-3-oxo-propyl]-5-methyl-pyrrolidin-2-one;

(-)- or (+)-5-Methyl-5-[3-oxo-3-[3-[4-[1-(trifluoromethyl)cyclopropyl]phenyl]azetidin-1-yl]propyl]pyrrolidin-2-one;

(+)- or (-)-5-Methyl-5-[3-oxo-3-[3-[4-[1-(trifluoromethyl)cyclopropyl]phenyl]azetidin-1-yl]propyl]pyrrolidin-2-one;

(-)- or (+)-5-[3-[3-[6-(3-Chlorophenoxy)-3-pyridyl]azetidin-1-yl]-3-oxo-propyl]-5-methyl-pyrrolidin-2-one;

(+)- or (-)-5-[3-[3-[6-(3-Chlorophenoxy)-3-pyridyl]azetidin-1-yl]-3-oxo-propyl]-5-methyl-pyrrolidin-2-one;

(4S)-4-[3-[3-[[2-Fluoro-4-(trifluoromethyl)phenyl]methoxy]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[[2-Fluoro-4-(trifluoromethyl)phenyl]methoxy]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4S)-4-[3-Oxo-3-[3-[4-[1-(trifluoromethyl)cyclopropyl]phenyl]azetidin-1-yl]propyl]oxazolidin-2-one;

(4R)-4-[3-Oxo-3-[3-[4-[1-(trifluoromethyl)cyclopropyl]phenyl]azetidin-1-yl]propyl]oxazolidin-2-one;

(4S)-4-[3-[3-[4-(2,4-Difluorophenyl)phenyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[4-(2,4-Difluorophenyl)phenyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-Oxo-3-[3-[4-(2,2,2-trifluoro-1,1-dimethyl-ethoxy)phenyl]azetidin-1-yl]propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[[2-Fluoro-4-(pentafluoro-λ^6-sulfanyl)phenyl]methoxy]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-[6-[(2,4-Difluorophenyl)methyl]-2-azaspiro[3.3]heptan-2-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[6-(2-Chlorophenoxy)-3-pyridyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-[6-(2-Chloro-4-fluoro-phenoxy)-2-azaspiro[3.3]heptan-2-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[4-(4-Fluorophenoxy)phenyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-Oxo-3-[3-[6-[4-(trifluoromethoxy)phenoxy]-3-pyridyl]azetidin-1-yl]propyl]oxazolidin-2-one;

(4R)-4-[3-Oxo-3-[6-[6-(trifluoromethyl)pyrazin-2-yl]oxy-2-azaspiro[3.3]heptan-2-yl]propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[2-(3-Chlorophenyl)ethynyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-Oxo-3-[3-[6-[3-(trifluoromethyl)pyrrolidin-1-yl]-3-pyridyl]azetidin-1-yl]propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[[2-Fluoro-4-(trifluoromethyl)phenyl]methoxy]azetidin-1-yl]-2-methyl-3-oxo-propyl]oxazolidin-2-one;

1-(3-((2-Fluoro-4-(trifluoromethyl)benzyl)oxy)azetidin-1-yl)-3-(1H-1,2,3-triazol-5-yl)propan-1-one;

3-(1H-1,2,3-Triazol-5-yl)-1-(3-(4-(1-(trifluoromethyl)cyclopropyl)phenyl)azetidin-1-yl)propan-1-one;

3-(1H-1,2,3-Triazol-5-yl)-1-(3-(4-((1,1,1-trifluoro-2-methylpropan-2-yl)oxy)phenyl)azetidin-1-yl)propan-1-one;

1-[3-[[2-Fluoro-4-(trifluoromethyl)phenyl]methoxy]azetidin-1-yl]-4-(1H-triazol-5-yl)butan-1-one;

4-(1H-Triazol-5-yl)-1-[3-[4-[1-(trifluoromethyl)cyclopropyl]phenyl]azetidin-1-yl]butan-1-one;

4-(1H-Triazol-5-yl)-1-[3-[4-(2,2,2-trifluoro-1,1-dimethyl-ethoxy)phenyl]azetidin-1-yl]butan-1-one;

4-(1H-Triazol-5-yl)-1-[3-[6-[4-(trifluoromethoxy)phenoxy]-3-pyridyl]azetidin-1-yl]butan-1-one;

4-(1H-Triazol-5-yl)-1-[6-[6-(trifluoromethyl)pyrazin-2-yl]oxy-2-azaspiro[3.3]heptan-2-yl]butan-1-one;

1-[3-[2-(3-Chlorophenyl)ethynyl]azetidin-1-yl]-4-(1H-triazol-5-yl)butan-1-one;

rac-4-(1H-Triazol-5-yl)-1-[3-[6-[3-(trifluoromethyl)pyrrolidin-1-yl]-3-pyridyl]azetidin-1-yl]butan-1-one;

4-(1H-Triazol-5-yl)-1-[3-[4-[3-(2,2,2-trifluoroethoxy)azetidin-1-yl]phenyl]azetidin-1-yl]butan-1-one;

1-[3-[[2-Fluoro-4-(trifluoromethyl)phenyl]methoxy]azetidin-1-yl]-3-(1H-pyrazol-5-yl)propan-1-one;

6-[3-[3-[[2-Fluoro-4-(trifluoromethyl)phenyl]methoxy]azetidin-1-yl]-3-oxo-propyl]-1H-pyridin-2-one;

6-[3-[3-[[2-Fluoro-4-(trifluoromethyl)phenyl]methoxy]azetidin-1-yl]-3-oxo-propyl]piperidin-2-one;

(-)-5-[3-[3-[[2-Fluoro-4-(trifluoromethyl)phenyl]methoxy]azetidin-1-yl]-3-oxo-propyl]morpholin-3-one;

(+)-5-[3-[3-[[2-Fluoro-4-(trifluoromethyl)phenyl]methoxy]azetidin-1-yl]-3-oxo-propyl]morpholin-3-one;

[(2S)-5-Oxopyrrolidin-2-yl]methyl 3-[[2-fluoro-4-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxylate;

[(2R)-5-Oxopyrrolidin-2-yl]methyl 3-[[2-fluoro-4-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxylate;

[(4S)-2-Oxooxazolidin-4-yl]methyl 3-[[2-fluoro-4-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxylate;

[(4R)-2-Oxooxazolidin-4-yl]methyl 3-[[2-fluoro-4-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxylate;

[(4S)-2-Oxooxazolidin-4-yl]methyl 3-[4-[1-(trifluoromethyl)cyclopropyl]phenyl]azetidine-1-carboxylate;

[(4S)-2-Oxooxazolidin-4-yl]methyl 6-[(2,4-difluorophenyl)methyl]-2-azaspiro[3.3]heptane-2-carboxylate;

[(4S)-2-Oxooxazolidin-4-yl]methyl 3-[4-(4-fluorophenoxy)phenyl]azetidine-1-carboxylate;

[(4R)-2-Oxooxazolidin-4-yl]methyl 6-[(2,4-difluorophenyl)methyl]-2-azaspiro[3.3]heptane-2-carboxylate;

[(4S)-2-Oxooxazolidin-4-yl]methyl 3-[6-(2-chlorophenoxy)-3-pyridyl]azetidine-1-carboxylate;

[(4S)-2-Oxooxazolidin-4-yl]methyl 3-[2-[2-(difluoromethyl)phenyl]ethynyl]azetidine-1-carboxylate;

[(4S)-2-Oxooxazolidin-4-yl]methyl 3-[6-[3-(trifluoromethyl)pyrrolidin-1-yl]-3-pyridyl]azetidine-1-carboxylate;

2-(1H-Triazol-5-yl)ethyl 3-[[2-fluoro-4-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxylate;

3-[[2-Fluoro-4-(trifluoromethyl)phenyl]methoxy]-N-[2-(1H-triazol-5-yl)ethyl]azetidine-1-carboxamide;

N-Methyl-N-[2-(1H-triazol-5-yl)ethyl]-3-[4-[1-(trifluoromethyl)cyclopropyl]phenyl]azetidine-1-carboxamide;

3-[[2-Fluoro-4-(trifluoromethyl)phenyl]methoxy]-N-methyl-N-[2-(1H-triazol-5-yl)ethyl]azetidine-1-carboxamide;

3-[4-(2-Chloro-4-methylsulfonyl-phenyl)phenyl]-N-methyl-N-[2-(1H-triazol-5-yl)ethyl]azetidine-1-carboxamide;

2-Methyl-4-(1H-triazol-5-yl)-1-[3-[4-[1-(trifluoromethyl)cyclopropyl]phenyl]azetidin-1-yl]butan-1-one;

3-Hydroxy-4-(1H-triazol-5-yl)-1-[3-[4-[1-(trifluoromethyl)cyclopropyl]phenyl]azetidin-1-yl]butan-1-one;

2-Fluoro-4-(1H-triazol-5-yl)-1-[3-[4-[1-(trifluoromethyl)cyclopropyl]phenyl]azetidin-1-yl]butan-1-one;

(4R)-4-[3-[3-[4-(N-Methylanilino)phenyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-[3-(5-tert-Butyl-2-pyridyl)azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[4-(2-chloro-4-methylsulfonyl-phenyl)phenyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[4-(Benzenesulfonyl)phenyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

2-[4-[1-[3-[(4R)-2-Oxooxazolidin-4-yl]propanoyl]azetidin-3-yl]phenyl]sulfonylacetonitrile;

(4R)-4-[3-Oxo-3-[3-[4-(trifluoromethylsulfonyl)phenyl]azetidin-1-yl]propyl]oxazolidin-2-one;

(4R)-4-[3-[3-(4-Cyclohexylsulfonylphenyl)azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

1-[5-[1-[3-[(4R)-2-Oxooxazolidin-4-yl]propanoyl]azetidin-3-yl]-2-pyridyl]cyclobutanecarbonitrile;

(4R)-4-[3-[3-[4-[(2-Methyl-3-pyridyl)oxy]phenyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[4-(4-Cyclopropylpyrimidin-2-yl)oxyphenyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[4-[3-(2,2-Dimethylpropyl)triazol-4-yl]phenyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[4-(4-Chloro-2-methylsulfonyl-phenyl)phenyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(+)- or (-)-(4R)-4-[3-[4-[(4-Methylsulfonylphenyl)-phenyl-methyl]-1-piperidyl]-3-oxo-propyl]oxazolidin-2-one;

(-)- or (+)-(4R)-4-[3-[4-[(4-Methylsulfonylphenyl)-phenyl-methyl]-1-piperidyl]-3-oxo-propyl]oxazolidin-2-one;

5-Chloro-2-[[5-[1-[3-[(4R)-2-oxooxazolidin-4-yl]propanoyl]azetidin-3-yl]-2-pyridyl]oxy]benzamide;

(-)- or (+)-[(4S)-2-Oxooxazolidin-4-yl]methyl 3-[6-[3-(trifluoromethyl)pyrrolidin-1-yl]-3-pyridyl]azetidine-1-carboxylate;

(+)- or (-)-[(4S)-2-Oxooxazolidin-4-yl]methyl 3-[6-[3-(trifluoromethyl)pyrrolidin-1-yl]-3-pyridyl]azetidine-1-carboxylate;

(5S)-5-[3-[3-[[2-Fluoro-4-(trifluoromethyl)phenyl]methoxy]azetidin-1-yl]-3-oxo-propyl]thiomorpholin-3-one;

(4R)-4-[3-[3-[4-[N-(Cyclopropylmethyl)anilino]phenyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-Oxo-3-[3-[4-(N-phenylanilino)phenyl]azetidin-1-yl]propyl]oxazolidin-2-one;

(4R)-4-[3-[3-(6-tert-Butyl-3-pyridyl)azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[6-[(5-Methoxy-2-pyridyl)-methyl-amino]-3-pyridyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[6-(N-Methylanilino)-3-pyridyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[6-(4-Isopropyl-N-methyl-anilino)-3-pyridyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[6-[N-(Cyclopropylmethyl)anilino]-3-pyridyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[4-[2-Methoxyethyl(3-pyridyl)amino]phenyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-[2-[4-Fluoro-2-(trifluoromethyl)phenyl]sulfonyl-2,6-diazaspiro[3.3]heptan-6-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-[2-(2,2-Dimethylpropylsulfonyl)-2,6-diazaspiro[3.3]heptan-6-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-Oxo-3-[3-[4-[3-(2,2,2-trifluoroethoxy)azetidin-1-yl]phenyl]azetidin-1-yl]propyl]oxazolidin-2-one;

(4R)-4-[3-Oxo-3-[3-[4-[3-(trifluoromethyl)azetidin-1-yl]phenyl]azetidin-1-yl]propyl]oxazolidin-2-one;

(4R)-4-[3-Oxo-3-[3-[2-[1-(trifluoromethyl)cyclopropyl]pyrimidin-5-yl]azetidin-1-yl]propyl]oxazolidin-2-one;

(4R)-4-[3-Oxo-3-[3-[6-[1-(trifluoromethyl)cyclopropyl]-3-pyridyl]azetidin-1-yl]propyl]oxazolidin-2-one;

(4R)-4-[3-Oxo-3-[3-[5-[3-(trifluoromethyl)pyrrolidin-1-yl]-2-pyridyl]azetidin-1-yl]propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[4-[3-(Methylsulfonylmethyl)azetidin-1-yl]phenyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-Oxo-3-[3-[5-[3-(trifluoromethyl)pyrrolidin-1-yl]pyrazin-2-yl]azetidin-1-yl]propyl]oxazolidin-2-one;

(4R)-4-[3-Oxo-3-[3-[5-[3-(trifluoromethyl)pyrrolidin-1-yl]pyrimidin-2-yl]azetidin-1-yl]propyl]oxazolidin-2-one;

(4R)-4-[3-Oxo-3-[3-[2-[3-(trifluoromethyl)pyrrolidin-1-yl]pyrimidin-5-yl]azetidin-1-yl]propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[5-(2-Chloro-4-methylsulfonyl-phenyl)-2-pyridyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-Oxo-3-[3-[3-[1-(trifluoromethyl)cyclopropyl]phenyl]azetidin-1-yl]propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[5-(2-Chloro-4-methylsulfonyl-phenyl)pyrazin-2-yl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-[3-(6-tert-Butylsulfonyl-3-pyridyl)azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[5-(4-Chloro-2-fluoro-phenyl)pyrimidin-2-yl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[5-(4-Chloro-2-fluoro-phenyl)-2-pyridyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[5-(2,4-Dichlorophenyl)-2-pyridyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[4-(5-Chloro-3-methylsulfonyl-2-pyridyl)phenyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[6-(2-Chloro-4-methylsulfonyl-phenyl)-3-pyridyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[6-(4-Chloro-2-methylsulfonyl-phenyl)-3-pyridyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[4-(6-Chloro-4-methylsulfonyl-3-pyridyl)phenyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-Oxo-3-[3-[4-[5-(trifluoromethyl)pyrazin-2-yl]phenyl]azetidin-1-yl]propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[4-(4-Chloro-2-fluoro-phenyl)-3-methylsulfonyl-phenyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[5-(4-Chloro-2-methylsulfonyl-phenyl)-2-pyridyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[5-(2-Chloro-4-methylsulfonyl-phenyl)pyrimidin-2-yl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[2-(2-Chloro-4-methylsulfonyl-phenyl)pyrimidin-5-yl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[4-[2-Methylsulfonyl-5-(trifluoromethyl)-3-pyridyl]phenyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-Oxo-3-[6-[[6-(trifluoromethyl)-3-pyridyl]methyl]-2-azaspiro[3.3]heptan-2-yl]propyl]oxazolidin-2-one;

(4R)-4-[3-[7-[[2-Fluoro-4-(trifluoromethyl)phenyl]methyl]-2,7-diazaspiro[3.5]nonan-2-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-Oxo-3-[3-[4-[4-(trifluoromethyl)pyrimidin-2-yl]oxyphenyl]azetidin-1-yl]propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[4-[4-Methylsulfonyl-2-(trifluoromethyl)phenyl]phenyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[3-Fluoro-4-[3-(trifluoromethyl)pyrrolidin-1-yl]phenyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[4-(1,1-Dioxothiolan-3-yl)phenyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[4-(2-Azaspiro[3.4]octan-2-yl)phenyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[4-(6,6-Difluoro-2-azaspiro[3.3]heptan-2-yl)phenyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-Oxo-3-[3-[4-[3-(trifluoromethyl)cyclobutyl]phenyl]azetidin-1-yl]propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[3-Fluoro-4-[3-(trifluoromethyl)azetidin-1-yl]phenyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-Oxo-3-[3-[4-[3-(trifluoromethyl)pyrrolidin-1-yl]phenyl]azetidin-1-yl]propyl]oxazolidin-2-one;

(4R)-4-[3-Oxo-3-[7-[6-(trifluoromethyl)pyridazin-3-yl]oxy-2-azaspiro[3.5]nonan-2-yl]propyl]oxazolidin-2-one;

(4R)-4-[3-[7-(4-Fluoro-2-methylsulfonyl-phenoxy)-2-azaspiro[3.5]nonan-2-yl]-3-oxo-propyl]oxazolidin-2-one;

N-[2-[3-[(4R)-2-Oxooxazolidin-4-yl]propanoyl]-2-azaspiro[3.5]nonan-7-yl]-3-(trifluoromethoxy)benzenesulfonamide;

(4R)-4-[3-[3-[5-(6,6-Difluoro-2-azaspiro[3.3]heptan-2-yl)pyrazin-2-yl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[5-(2-Azaspiro[3.4]octan-2-yl)pyrazin-2-yl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[6-(6,6-Difluoro-2-azaspiro[3.3]heptan-2-yl)-3-pyridyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[6-(2-Azaspiro[3.4]octan-2-yl)-3-pyridyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-[7-[2-Fluoro-4-(trifluoromethyl)phenyl]sulfonyl-2,7-diazaspiro[3.5]nonan-2-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[6-[3-Hydroxy-3-(trifluoromethyl)azetidin-1-yl]-3-pyridyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[4-(3,5-Dimethylpyrazol-1-yl)phenyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[6-[3-Hydroxy-3-(trifluoromethyl)pyrrolidin-1-yl]-3-pyridyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-Oxo-3-[2-[4-(trifluoromethyl)phenyl]sulfonyl-2,6-diazaspiro[3.3]heptan-6-yl]propyl]oxazolidin-2-one;

(4R)-4-[3-Oxo-3-[2-[2-(trifluoromethoxy)phenyl]sulfonyl-2,6-diazaspiro[3.3]heptan-6-yl]propyl]oxazolidin-2-one;

(4R)-4-[3-Oxo-3-[2-[3-(trifluoromethoxy)phenyl]sulfonyl-2,6-diazaspiro[3.3]heptan-6-yl]propyl]oxazolidin-2-one;

(4R)-4-[3-Oxo-3-[2-[4-(trifluoromethoxy)phenyl]sulfonyl-2,6-diazaspiro[3.3]heptan-6-yl]propyl]oxazolidin-2-one;

2-[[2-[3-[(4R)-2-Oxooxazolidin-4-yl]propanoyl]-2,6-diazaspiro[3.3]heptan-6-yl]methyl]benzenesulfonamide;

N-[2-[3-[(4R)-2-Oxooxazolidin-4-yl]propanoyl]-2-azaspiro[3.3]heptan-6-yl]-3-(trifluoromethyl)benzenesulfonamide;

(4R)-4-[3-Oxo-3-[3-[[4-(trifluoromethyl)phenyl]methylamino]azetidin-1-yl]propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[[2-Fluoro-5-(trifluoromethyl)phenyl]methylamino]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-[6-[(4-Fluoro-2-methylsulfonyl-phenyl)methyl]-2-azaspiro[3.3]heptan-2-yl]-3-oxo-propyl]oxazolidin-2-one;

N-[[1-[3-[(4R)-2-Oxooxazolidin-4-yl]propanoyl]-4-piperidyl]methyl]-4-(trifluoromethyl)benzenesulfonamide;

N-[[1-[3-[(4R)-2-Oxooxazolidin-4-yl]propanoyl]-4-piperidyl]methyl]-4-(trifluoromethoxy)benzenesulfonamide;

(4R)-4-[3-[3-[6-(3-Hydroxy-3-methyl-azetidin-1-yl)-3-pyridyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-Oxo-3-[3-[6-[3-(trifluoromethyl)azetidin-1-yl]-3-pyridyl]azetidin-1-yl]propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[[2-Fluoro-4-(trifluoromethyl)phenyl]methyl-methyl-amino]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-Oxo-3-[3-(6-spiro[3.3]heptan-2-yl-3-pyridyl)azetidin-1-yl]propyl]oxazolidin-2-one;

(4R)-4-[3-Oxo-3-[3-(5-spiro[3.3]heptan-2-ylpyrazin-2-yl)azetidin-1-yl]propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[3-[5-(2,2-Dimethylpropyl)-1,3,4-oxadiazol-2-yl]-1-bicyclo[1.1.1]pentanyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-Oxo-3-[3-[[4-(trifluoromethylsulfonyl)phenyl]methoxy]azetidin-1-yl]propyl]oxazolidin-2-one;

(4R)-4-[3-Oxo-3-[3-[5-[6-(trifluoromethyl)-3-pyridyl]-1,2,4-oxadiazol-3-yl]azetidin-1-yl]propyl]oxazolidin-2-one;

(4R)-4-[3-Oxo-3-[3-[5-[3-(trifluoromethyl)-1-bicyclo[1.1.1]pentanyl]-1,2,4-oxadiazol-3-yl]azetidin-1-yl]propyl]oxazolidin-2-one;

(4R)-4-[3-Oxo-3-[3-[[3-(trifluoromethylsulfonyl)phenyl]methoxy]azetidin-1-yl]propyl]oxazolidin-2-one;

Methyl 5-chloro-2-[[5-[1-[3-[(4R)-2-oxooxazolidin-4-yl]propanoyl]azetidin-3-yl]-2-pyridyl]oxy]benzoate;

(4R)-4-[3-Oxo-3-[3-[[3-(trifluoromethylsulfonyl)phenyl]methoxy]azetidin-1-yl]propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[6-[3-(1-Hydroxy-1-methyl-ethyl)azetidin-1-yl]-3-pyridyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[4-[1-(Hydroxymethyl)cyclopropyl]phenyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[6-(5-Oxa-2-azaspiro[3.4]octan-2-yl)-3-pyridyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[6-(2,2-Difluoro-5-azaspiro[2.4]heptan-5-yl)-3-pyridyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-Oxo-3-[3-[4-[5-(trifluoromethyl)pyrazin-2-yl]oxyphenyl]azetidin-1-yl]propyl]oxazolidin-2-one;

(4R)-4-[3-Oxo-3-[3-[5-[[1-(trifluoromethyl)cyclopropyl]methylamino]-2-pyridyl]azetidin-1-yl]propyl]oxazolidin-2-one;

(4R)-4-[3-Oxo-3-[3-[5-[[1-(trifluoromethyl)cyclopropyl]methylamino]pyrazin-2-yl]azetidin-1-yl]propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[4-(3-Cyclopropyl-1H-1,2,4-triazol-5-yl)phenyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-Oxo-3-[3-[4-[3-[1-(trifluoromethyl)cyclopropyl]-1H-1,2,4-triazol-5-yl]phenyl]azetidin-1-yl]propyl]oxazolidin-2-one;

(4R)-4-[3-[6-[(3-Methylsulfonylphenyl)methyl]-2-azaspiro[3.3]heptan-2-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-[6-[(4-Methylsulfonylphenyl)methyl]-2-azaspiro[3.3]heptan-2-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-Oxo-3-[6-[[6-(trifluoromethyl)pyridazin-3-yl]methyl]-2-azaspiro[3.3]heptan-2-yl]propyl]oxazolidin-2-one;

(4R)-4-[3-Oxo-3-[6-[[2-(trifluoromethyl)pyrimidin-5-yl]methyl]-2-azaspiro[3.3]heptan-2-yl]propyl]oxazolidin-2-one;

(4R)-4-[3-Oxo-3-[6-[[5-(trifluoromethyl)pyrimidin-2-yl]methyl]-2-azaspiro[3.3]heptan-2-yl]propyl]oxazolidin-2-one;

(4R)-4-[3-[6-[(3-Fluoro-5-methylsulfonyl-phenyl)methyl]-2-azaspiro[3.3]heptan-2-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-[6-(3-Cyclopropyl-1,2,4-triazol-1-yl)-2-azaspiro[3.3]heptan-2-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-Oxo-3-[6-[[3-(trifluoromethylsulfonyl)phenyl]methyl]-2-azaspiro[3.3]heptan-2-yl]propyl]oxazolidin-2-one;

(4R)-4-[3-Oxo-3-[6-[[4-(trifluoromethylsulfonyl)phenyl]methyl]-2,6-diazaspiro[3.3]heptan-2-yl]propyl]oxazolidin-2-one;

(4R)-4-[3-Oxo-3-[7-[[6-(trifluoromethyl)-3-pyridyl]methyl]-2-azaspiro[3.5]nonan-2-yl]propyl]oxazolidin-2-one;

(4R)-4-[3-Oxo-3-[7-[[5-(trifluoromethyl)-2-pyridyl]methyl]-2-azaspiro[3.5]nonan-2-yl]propyl]oxazolidin-2-one;

(4R)-4-[3-Oxo-3-[7-[[5-(trifluoromethyl)pyrazin-2-yl]methyl]-2-azaspiro[3.5]nonan-2-yl]propyl]oxazolidin-2-one;

(4R)-4-[3-[7-[[6-(Difluoromethoxy)-3-pyridyl]methyl]-2-azaspiro[3.5]nonan-2-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-[7-[(4-Methylsulfonylphenyl)methyl]-2,7-diazaspiro[3.5]nonan-2-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-[7-[(3-Methylsulfonylphenyl)methyl]-2,7-diazaspiro[3.5]nonan-2-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-Oxo-3-[7-[[4-(trifluoromethylsulfonyl)phenyl]methyl]-2,7-diazaspiro[3.5]nonan-2-yl]propyl]oxazolidin-2-one;

(4R)-4-[3-Oxo-3-[7-[[3-(trifluoromethylsulfonyl)phenyl]methyl]-2,7-diazaspiro[3.5]nonan-2-yl]propyl]oxazolidin-2-one;

(4R)-4-[3-Oxo-3-[7-[[6-(trifluoromethyl)-3-pyridyl]methyl]-2,7-diazaspiro[3.5]nonan-2-yl]propyl]oxazolidin-2-one;

(4R)-4-[3-Oxo-3-[7-[[5-(trifluoromethyl)-2-pyridyl]methyl]-2,7-diazaspiro[3.5]nonan-2-yl]propyl]oxazolidin-2-one;

(4R)-4-[3-Oxo-3-[6-[[6-(trifluoromethyl)-3-pyridyl]methyl]-2-azaspiro[3.4]octan-2-yl]propyl]oxazolidin-2-one;

Methyl 5-chloro-2-[[5-[1-[3-[(4R)-2-oxooxazolidin-4-yl]propanoyl]azetidin-3-yl]-2-pyridyl]oxy]benzoate;

cis-(4R)-4-[3-Oxo-3-[3-[6-[4-(trifluoromethyl)cyclohexyl]-3-pyridyl]azetidin-1-yl]propyl]oxazolidin-2-one;

trans-(4R)-4-[3-Oxo-3-[3-[6-[4-(trifluoromethyl)cyclohexyl]-3-pyridyl]azetidin-1-yl]propyl]oxazolidin-2-one;

cis-(4R)-4-[3-Oxo-3-[3-[6-[3-(trifluoromethyl)cyclobutyl]-3-pyridyl]azetidin-1-yl]propyl]oxazolidin-2-one;

trans-(4R)-4-[3-Oxo-3-[3-[6-[3-(trifluoromethyl)cyclobutyl]-3-pyridyl]azetidin-1-yl]propyl]oxazolidin-2-one;

(-)- or (+)-(4R)-4-[3-[3-[6-[3-Hydroxy-3-(trifluoromethyl)pyrrolidin-1-yl]-3-pyridyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(+)- or (-)-(4R)-4-[3-[3-[6-[3-Hydroxy-3-(trifluoromethyl)pyrrolidin-1-yl]-3-pyridyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(-)- or (+)-(4R)-4-[3-[3-[6-[3-Hydroxy-3-(trifluoromethyl)pyrrolidin-1-yl]-3-pyridyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(+)- or (-)-(4R)-4-[3-[3-[6-[3-Hydroxy-3-(trifluoromethyl)pyrrolidin-1-yl]-3-pyridyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(-)- or (+)-(4R)-4-[3-Oxo-3-[3-[2-[3-(trifluoromethyl)pyrrolidin-1-yl]pyrimidin-5-yl]azetidin-1-yl]propyl]oxazolidin-2-one;

(+)- or (-)-(4R)-4-[3-Oxo-3-[3-[2-[3-(trifluoromethyl)pyrrolidin-1-yl]pyrimidin-5-yl]azetidin-1-yl]propyl]oxazolidin-2-one;

(-)- or (+)-(4R)-4-[3-Oxo-3-[6-[[6-(trifluoromethyl)-3-pyridyl]methyl]-2-azaspiro[3.4]octan-2-yl]propyl]oxazolidin-2-one;

(+)- or (-)-(4R)-4-[3-Oxo-3-[6-[[6-(trifluoromethyl)-3-pyridyl]methyl]-2-azaspiro[3.4]octan-2-yl]propyl]oxazolidin-2-one;

3-[4-(4-Chloro-2-methylsulfonyl-phenyl)phenyl]-N-[(2-oxooxazolidin-4-yl)methyl]azetidine-1-carboxamide;

4-[3-Oxo-3-[6-[[6-(trifluoromethyl)-3-pyridyl]methyl]-2-azaspiro[3.3]heptan-2-yl]propyl]imidazolidin-2-one;

4-[3-Oxo-3-[3-[4-[1-(trifluoromethyl)cyclopropyl]phenyl]azetidin-1-yl]propyl]imidazolidin-2-one;

4-[3-[3-[[2-Fluoro-4-(trifluoromethyl)phenyl]methoxy]azetidin-1-yl]-3-oxo-propyl]imidazolidin-2-one;

4-[3-[3-[4-(4-Chloro-2-methylsulfonyl-phenyl)phenyl]azetidin-1-yl]-3-oxo-propyl]imidazolidin-2-one;

(-)- or (+)-4-[3-[3-[4-(4-Chloro-2-methylsulfonyl-phenyl)phenyl]azetidin-1-yl]-3-oxo-propyl]imidazolidin-2-one; and

(+)- or (-)-4-[3-[3-[4-(4-Chloro-2-methylsulfonyl-phenyl)phenyl]azetidin-1-yl]-3-oxo-propyl]imidazolidin-2-one.

16. The compound of formula (I) according to claim 15, or a pharmaceutically acceptable salt thereof, selected from:

(+)-5-[3-[3-[[2-fluoro-4-(trifluoromethyl)phenyl]methoxy]azetidin-1-yl]-3-oxo-propyl]pyrrolidin-2-one;

(+)-5-[3-Oxo-3-[3-[4-[1-(trifluoromethyl)cyclopropyl]phenyl]azetidin-1-yl]propyl]pyrrolidin-2-one;

(+)-5-[3-[3-[4-(2,4-Difluorophenyl)phenyl]azetidin-1-yl]-3-oxo-propyl]pyrrolidin-2-one;

(4R)-4-[3-[3-[[2-Fluoro-4-(trifluoromethyl)phenyl]methoxy]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-Oxo-3-[3-[4-[1-(trifluoromethyl)cyclopropyl]phenyl]azetidin-1-yl]propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[4-(2,4-Difluorophenyl)phenyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[6-(2-Chlorophenoxy)-3-pyridyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[4-(N-Methylanilino)phenyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[4-(4-Chloro-2-methylsulfonyl-phenyl)phenyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[4-[N-(Cyclopropylmethyl)anilino]phenyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-[3-[6-[N-(Cyclopropylmethyl)anilino]-3-pyridyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;

(4R)-4-[3-Oxo-3-[3-[4-[3-(2,2,2-trifluoroethoxy)azetidin-1-yl]phenyl]azetidin-1-yl]propyl]oxazolidin-2-one;
(4R)-4-[3-Oxo-3-[3-[4-[3-(trifluoromethyl)azetidin-1-yl]phenyl]azetidin-1-yl]propyl]oxazolidin-2-one;
(4R)-4-[3-[3-[5-(4-Chloro-2-fluoro-phenyl)pyrimidin-2-yl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;
(4R)-4-[3-[3-[5-(4-Chloro-2-fluoro-phenyl)-2-pyridyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;
(4R)-4-[3-[3-[5-(2,4-Dichlorophenyl)-2-pyridyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;
(4R)-4-[3-Oxo-3-[6-[[6-(trifluoromethyl)-3-pyridyl]methyl]-2-azaspiro[3.3]heptan-2-yl]propyl]oxazolidin-2-one;
(4R)-4-[3-[7-[[2-Fluoro-4-(trifluoromethyl)phenyl]methyl]-2,7-diazaspiro[3.5]nonan-2-yl]-3-oxo-propyl]oxazolidin-2-one;
(4R)-4-[3-[3-[4-[4-Methylsulfonyl-2-(trifluoromethyl)phenyl]phenyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;
(4R)-4-[3-[3-[3-Fluoro-4-[3-(trifluoromethyl)pyrrolidin-1-yl]phenyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;
(4R)-4-[3-Oxo-3-[3-[4-[3-(trifluoromethyl)cyclobutyl]phenyl]azetidin-1-yl]propyl]oxazolidin-2-one;
(4R)-4-[3-[3-[6-(2-Azaspiro[3.4]octan-2-yl)-3-pyridyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;
(4R)-4-[3-[3-[3-[5-(2,2-Dimethylpropyl)-1,3,4-oxadiazol-2-yl]-1-bicyclo[1.1.1]pentanyl]azetidin-1-yl]-3-oxo-propyl]oxazolidin-2-one;
(4R)-4-[3-Oxo-3-[3-[[4-(trifluoromethylsulfonyl)phenyl]methoxy]azetidin-1-yl]propyl]oxazolidin-2-one;
(4R)-4-[3-Oxo-3-[7-[[6-(trifluoromethyl)-3-pyridyl]methyl]-2-azaspiro[3.5]nonan-2-yl]propyl]oxazolidin-2-one; and
cis-(4R)-4-[3-Oxo-3-[3-[6-[4-(trifluoromethyl)cyclohexyl]-3-pyridyl]azetidin-1-yl]propyl]oxazolidin-2-one.

17. A compound of formula (I) according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, for use as therapeutically active substance.

18. A pharmaceutical composition comprising a compound of formula (I) according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, and a therapeutically inert carrier.

~~19. The use of a compound of formula (I) according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, or of a pharmaceutical composition according to claim 18 for the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer, mental disorders and/or inflammatory bowel disease in a mammal.~~

~~20. The use of a compound of formula (I) according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, or of a pharmaceutical composition according to claim 18 for the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain, spasticity associated with pain, abdominal pain, abdominal pain associated with irritable bowel syndrome and/or visceral pain in a mammal.~~

~~21.~~19. A compound of formula (I) according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 18 for use in the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer, mental disorders and/or inflammatory bowel disease in a mammal.

~~22.~~20. A compound of formula (I) according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 18 for use in the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain, spasticity associated with pain,

abdominal pain, abdominal pain associated with irritable bowel syndrome and/or visceral pain in a mammal.

~~23.~~21. ~~The use~~Use of a compound of formula (I) according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, ~~for~~ in the preparation of a medicament for the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer, mental disorders and/or inflammatory bowel disease in a mammal.

~~24.~~22. ~~The use~~Use of a compound of formula (I) according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, ~~for~~ in the preparation of a medicament for the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain, spasticity associated with pain, abdominal pain, abdominal pain associated with irritable bowel syndrome and/or visceral pain in a mammal.

~~25. A method for the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer, mental disorders, and/or inflammatory bowel disease in a mammal, which method comprises administering an effective amount of a compound of formula (I) according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, or of a pharmaceutical composition according to claim 18 to the mammal.~~

~~26. A method for the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain, spasticity associated with pain in a mammal, abdominal pain, abdominal pain associated with irritable bowel syndrome and/or visceral pain which method comprises administering an effective amount of a compound of formula (I) according to any one of claims 1 to 16, or a~~

~~pharmaceutically acceptable salt thereof, or of a pharmaceutical composition according to claim 18 to the mammal.~~